Consistently, Tolvaptan, a highly selective V2R antagonist approved for the treatment of ADPKD, has been shown to significantly reduce kidney volume and renal function decline in phase three clinical trials (Cassola et al., 1993). Here, AVPR2 is linked to autosomal dominant polycystic kidney disease.